

关键基因的肿瘤边界特征和 Kaplan-Meier 生存曲线
首先，我们继续利用空间转录组学生成图 8A 所示的 ST 特征图，该图更清晰地描绘了所选切片内肿
瘤边界、恶性区域和正常组织的分布。此外，在比较两组时，高 MFRS 组的总生存率显著低于低 MFRS 组
(p < 0.0001)(图 8B)。我们对 MYH11、KDM5B、CTNNB1、CD44、CUX1、TEAD1、HOXA10、PBX1 和
FOSL2 等关键基因进行了生存曲线分析。除 MYH11 外，所有基因在高表达组中的生存率均低于低表达组
(补充图 6A)。
我们还可视化了 10 个预后基因的表达模式，与之前的观察结果类似，只有 DES 和 PCP4 在低 MFRS
组中的表达水平相对于高 MFRS 组更高 (图 8C)。此外，我们分析了预后基因在不同状态类别 (如年龄、种
族、分期和分级) 中的分布 (图 8D)。最后，我们检查了高 MFRS 组和低 MFRS 组之间四种免疫相关药物
(小白菊内酯、甲磺酸奥巴托卡、FTI.277 和 AZD8055) 的 IC50 值 (图 8E)。所有四种药物的 IC50 值在高
MFRS 组中较低，而在低 MFRS 组中较高。

图 8 肿瘤边界特征、预后模型差异和免疫药物治疗预测。A ST 特征图显示了所选组织切片中宫颈癌
肿瘤边界 (Bdy)、恶性区域 (Mal，Mal1) 和正常组织 (Normal) 的分布。B Kaplan-Meier 生存曲线显示了高
MFRS 组和低 MFRS 组之间的生存差异。C 说明了高 MFRS 组和低 MFRS 组之间 10 个风险基因的表达差
异。D 饼图显示了研究中不同状态、年龄、种族、分期和分级的比例。E 箱线图显示了高 MFRS 组和低
MFRS 组中四种免疫药物的 IC50 值内胚层形成和细胞外基质分解。相比之下，下调基因主要富集在钾离
子稳态、杀死其他生物体的细胞、轴丝组装和轴丝组装 (图 9F)

Tumor Border Characterization and Kaplan–Meier Survival 
Curves of Key Genes
To begin, we continued utilizing spatial transcriptomics 
to generate the ST feature map shown in Fig. 8A, which 
provided a clearer depiction of the distribution of tumor 
borders, malignant regions, and normal tissues within the 
selected sections. Furthermore, when comparing the two 
groups, the high MFRS group exhibited a significantly 
lower overall survival rate than the low MFRS group (p
< 0.0001) (Fig. 8B). We conducted survival curve analysis 
for key genes such as MYH11, KDM5B, CTNNB1, CD44, 
CUX1, TEAD1, HOXA10, PBX1, and FOSL2. With the 
exception of MYH11, all genes showed a lower survival 
rate in the high-expression group compared to the low expression group (Supplementary Fig. 6A).
We also visualized the expression patterns of the 10 
prognostic genes, and similar to previous observations, 
only DES and PCP4 exhibited higher expression levels in the low MFRS group relative to the high MFRS 
group (Fig.  8C). Additionally, we analyzed the distribution of the prognostic genes across various status categories, such as age, race, stage, and grade (Fig. 8D). Finally, 
we examined the IC50 values of four immune-related 
drugs—Parthenolide, Obatoclax Mesylate, FTI.277, and 
AZD8055—between the high MFRS and low MFRS 
groups (Fig. 8E). The IC50 values of all four drugs were 
lower in the high MFRS group, while they were higher in 
the low MFRS group.

Fig. 8 Tumor boundary characterization, prognostic model differences, and immune drug treatment prediction. A ST feature maps displayed 
the distribution of cervical cancer tumor boundaries (Bdy), malignant regions (Mal, Mal1), and normal tissue (Normal) in selected tissue sections. 
B Kaplan–Meier survival curves showed survival differences between the high MFRS and low MFRS groups. C Expression differences of 10 risk genes 
between the high MFRS and low MFRS groups were illustrated. D A pie chart displayed the proportions of different statuses, ages, races, stages, 
and grades in the study. E Boxplots showed the IC50 values of four immune drugs in the high MFRS and low MFRS groups